I did not say he was just browsing around and I do not disagree that that is what he was there to do. I think you’re wrong that he was there to draft the SAP. I know a thing or two about drafting regulatory filings and there is no way he was the person drafting such a document. As I said, I have no doubt he was one of many who were likely consulted. He likely had good advice, but his most likely focus would be on getting to the next level, which is getting to trials and trial structures that would enable biomarker approvals so that DCVax could be a general cancer vaccine more quickly than doing 50 different trials, for cancers of every limb and organ.
That was his expertise. He was not a regulatory advisor in the context that you suggest. And that was not his role clearly nor his expertise. He comes with contacts and knowledge about how Keytruda got general approval for any cancer with certain biomarkers. And while his knowledge was probably generally useful, his information was likely very narrow and quickly communicated I expect. So after some quick conversations as an employee, and probably some ongoing consultations, he probably was not as key an employee as you seem to think. And, also, he was likely there for Merck’s benefit as well, or he’d likely not have gone directly back to Merck.
Market Data 
Markets 
AI
